Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer

INTRODUCTION: Androgen deprivation therapy (ADT) is the mainstay for advanced, hormone-sensitive prostate cancer, and options include surgical castration, luteinizing hormone-releasing hormone (LHRH) agonist, and more recently, gonadotropin releasing hormone (GnRH) antagonist therapy. Our understand...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Expert Opin Pharmacother
Egile Nagusiak: Clinton, Timothy N., Woldu, Solomon L., Raj, Ganesh V.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2017
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7171911/
https://ncbi.nlm.nih.gov/pubmed/28480768
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14656566.2017.1328056
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak